Innate Pharma announces intention to conduct a registered offering in the United States
June 12, 2019Innate Pharma, S.A. (Euronext Paris: IPH) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the...Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
June 12, 2019Multicohort, multi-center, international Phase II study to evaluate the efficacy and safety of IPH4102 in patients with advanced T-cell lymphoma is ongoing Sézary syndrome cohort of the TELLOMAK...Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
June 6, 2019TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the International...Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
May 31, 2019The findings describe potential first-in-class NKp46 NKCEs, a new generation of multifunctional antibody-based molecules for fighting cancer The NKCE technology provides a versatile platform to...Innate Pharma announces publication on next generation immunotherapies targeting the adenosine pathway in “Cell Reports”
May 23, 2019The production of adenosine via CD39 and CD73 enzymes participates in an immunosuppressive tumor microenvironment. Perrot et al. generated two antibodies, IPH5201 and IPH5301, targeting human CD39...Outcome of Annual General Meeting of May 22, 2019
May 23, 2019Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 22, 2019, in Marseille, France...
